GRTS - Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will webcast an event with key opinion leaders who will present on neoantigen-based immunotherapy on Monday, June 3, 2019 from 6:30-8:00 a.m. CT in Chicago.

Agenda:

• “Increasing Evidence that Neoantigens are Critical for Immuno-oncology” presented by Naiyer A. Rizvi, M.D., Columbia University Medical Center
• “Leveraging Neoantigens Therapeutically” presented by Charles G. Drake, M.D., Ph.D., Columbia University Medical Center
• “Optimal Clinical Trial Design for the Evaluation of Personalized Cancer Vaccines in the era of Immune Checkpoint Inhibitors” presented by Daniel Catenacci, M.D., University of Chicago

A live audio webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy in Phase 1 clinical testing. Gritstone’s second product candidate, SLATE-001, is a shared neoantigen (“off-the-shelf”) immunotherapy which is advancing towards the clinic. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com